184 related articles for article (PubMed ID: 8727343)
1. [A study of the significance of serum beta 2-microglobulin levels in patients with multiple myeloma--analyzes as a marker of renal dysfunction and as a marker of tumor cell mass].
Nishinarita S; Shimada H; Suzuki R; Kishigami Y; Sawada U; Horie T
Rinsho Ketsueki; 1996 Mar; 37(3):201-7. PubMed ID: 8727343
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
[TBL] [Abstract][Full Text] [Related]
4. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
6. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
Ujiie T; Maruta H; Ito N
Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
Scudla V; Vavrdová V; Budíková M; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
[TBL] [Abstract][Full Text] [Related]
8. [Application of urinary free dopamine as a marker of renal function, and comparison with other renal marker].
Komori T; Habuchi Y; Inoue H; Sakai T; Suzuki K; Ohtsuka K; Tanaka H; Fujita N; Yoshimura M
Rinsho Byori; 1997 Jul; 45(7):679-84. PubMed ID: 9256016
[TBL] [Abstract][Full Text] [Related]
9. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
10. [Serum beta 2-microglobulin in multiple myeloma. II. Its significance in monitoring the disease].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 May; 37(5):479-87. PubMed ID: 1842146
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of serum cystatin C and beta2 microglobulin, urinary beta2 microglobulin and N-acetyl-beta-D-glucosaminidase in early acute renal failure after liver transplantation.
Hei ZQ; Li XY; Shen N; Pang HY; Zhou SL; Guan JQ
Chin Med J (Engl); 2008 Jul; 121(14):1251-6. PubMed ID: 18713542
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Karkantaris C; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Pizzolo G; Pangalis GA
Haematologica; 2002 Jul; 87(7):701-8; discussion 708. PubMed ID: 12091120
[TBL] [Abstract][Full Text] [Related]
13. Beta 2-microglobulin: its significance and clinical usefulness.
Bethea M; Forman DT
Ann Clin Lab Sci; 1990; 20(3):163-8. PubMed ID: 2188562
[TBL] [Abstract][Full Text] [Related]
14. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of urinary free dopamine as a marker of renal function].
Komori T; Yoshimura M; Inoue H; Suzuki K; Yasumura T; Morimoto T
Rinsho Byori; 1996 May; 44(5):477-82. PubMed ID: 8676569
[TBL] [Abstract][Full Text] [Related]
16. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
17. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
Kraj M; Maj S; Pogłód R; Rostkowska J
Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
[TBL] [Abstract][Full Text] [Related]
18. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
19. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Willems HL; Wetzels JF
Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
[TBL] [Abstract][Full Text] [Related]
20. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
